1. Bayer buying KaNDy for $425M to get menopause market — Putin says Russian COVID-19 vaccine will be ready January 1 — Eisai creating new US HQ in New Jersey — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

52-week low; not a good sign

Discussion in 'Celgene' started by anonymous, May 22, 2018 at 11:46 AM.

  1. anonymous

    anonymous Guest

    Don't forget that external factors can influence the stock price. Amgen presented (early!) data that week for AMG 420, an ADC targeting BCMA, that resulted in prolonged remissions in MM patients. This represents a possible threat to bb2121, although it is too early to tell where the comparative advantages lie.
     

  2. anonymous

    anonymous Guest

    And now another discontinued trial and concept further decline the stock. This company better get its act together. The BOD needs to reevaluate sooner than later.